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Current	Prospects	And	Future	Challenges	For	Nasal	Vaccine	Delivery		1 
	2 
Abstract	3 
Nasal	 delivery	offers	many	benefits	 over	 traditional	 approaches	 to	 vaccine	 administration.	4 
These	 include	 ease	 of	 administration	without	 needles	 that	 reduces	 issues	 associated	with	5 
needlestick	injuries	and	disposal.	Additionally,	this	route	offers	easy	access	to	a	key	part	of	6 
the	immune	system	that	can	stimulate	other	mucosal	sites	throughout	the	body.	Increased	7 
acceptance	 of	 nasal	 vaccine	 products	 in	 both	 adults	 and	 children	 has	 led	 to	 a	 burgeoning	8 
pipeline	 of	 nasal	 delivery	 technology.	 Key	 challenges	 and	 opportunities	 for	 the	 future	will	9 
include	 translating	 in	vivo	data	 to	 clinical	outcomes.	Particular	 focus	 should	be	brought	 to	10 
designing	delivery	strategies	that	take	into	account	the	broad	range	of	diseases,	populations	11 
and	healthcare	delivery	settings	that	stand	to	benefit	from	this	unique	mucosal	route.		12 
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In	 this	 review	the	current	 state	of	 the	art	 in	nasal	vaccine	delivery	will	be	described	along	18 
with	future	prospects.	A	brief	introduction	to	the	anatomy	and	physiology	of	the	nasal	cavity	19 
will	 highlight	 the	 advantages	 and	 disadvantages	 of	 the	 route.	 Encapsulation	 and	20 
presentation	methods	along	with	particular	 formulation	considerations	 for	 the	nasal	 route	21 
will	also	be	discussed.		22 
	23 
There	 are	 many	mucosal	 routes	 which	 have	 been	 regarded	 as	 potential	 sites	 for	 vaccine	24 
delivery	 such	as	oral,	 nasal,	 pulmonary,	 conjunctival,	 rectal	 and	vaginal	mucosa.	However,	25 
for	practical	and	cultural	reasons	researchers	have	tended	to	focus	only	on	oral,	nasal,	and	26 
pulmonary	 administration.1	 Needle-free	 vaccines	 offer	 many	 advantages	 over	 traditional	27 
vaccination	approaches	including	convenience,	cost,	ease	of	administration	and	disposal.		28 
There	 are	 several	 needle	 free	 methods	 of	 vaccination	 such	 as	 transdermal	 delivery	 and	29 
mucosal	delivery.2,3	Mucosal	immunization	has	been	successfully	used	in	human	vaccination.	30 
The	 human	mucosal	 immune	 system	 is	 large	 and	 specialized	 in	 performing	 inspection	 for	31 
foreign	 antigens	 to	 protect	 the	 surfaces	 themselves	 and	 of	 course	 human	 body	 interior.	32 
Since	 most	 infections	 affect	 or	 start	 from	 mucosal	 surfaces,	 using	 a	 mucosal	 route	 of	33 
vaccination	is	of	great	interest	and	provides	a	rational	reason	to	induce	a	protective	immune	34 
response.3		Nasal	delivery	of	vaccine	offers	an	easily	accessible	route	to	the	immune	system.	35 
The	 nose	 has	 the	 function	 of	 olfactory	 detection	 (sense	 of	 smell)	 and	 also	 filtration,	36 
humidification	 and	 temperature	 control	 of	 air	 as	 it	 enters	 the	 respiratory	 system.	Moving	37 
from	 front	 to	 back	 the	 areas	 of	 the	 nasal	 cavity	 are	 the	 nasal	 vestibule,	 the	 respiratory	38 
region,	and	the	olfactory	region.	The	nasal	cavity	 is	divided	by	the	septum	to	form	the	 left	39 
and	 right	 nares,	 which	 lead	 into	 the	 left	 and	 right	 choana	 before	 opening	 onto	 the	40 
nasopharynx	 at	 the	 top	 of	 the	 throat.	 	 The	 turbinates	 bound	 the	 nasal	 walls	 and	 are	41 
responsible	for	air	conditioning	and	the	large	mucosal	surface	area	of	the	nasal	cavity.	The	42 
nose	is	also	the	main	port	of	entry	for	many	pathogens.	The	first	barrier	to	foreign	bodies	is	43 
hair	at	the	entrance	to	the	nares,	the	nostrils,	which	successfully	keeps	out	larger	particles.	44 
The	 entire	 surface	 of	 the	 nasal	 cavity	 is	 covered	 in	 a	 mucus	 layer,	 which	 traps	 smaller	45 
particles.	Mucus	is	an	aqueous,	viscoelastic	and	adhesive	gel	4	that	contains	several	types	of	46 
mucins	 (abbreviated	 to	 MUC)	 MUC1,	 MUC4,	 MUC5A	 and	 MUC5B,	 MUC16,	 that	 are	47 
produced	by	either	goblet	cells	or	mucus	subglands.5,	6	Cilia	perform	a	mechanical	 clearing	48 
role	termed	mucociliary	clearance	by	beating	and	thus	transporting	the	mucus	blanket	with	49 
entrapped	pathogens	to	the	back	of	the	throat	at	a	rate	of	5-6	mm	per	minute,	either	to	be	50 
destroyed	 in	 the	 stomach	 or	 expectorated	 via	 sneezing	 and/or	 coughing.	 This	 function	51 
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minimises	the	amount	of	particles	able	to	enter	the	body	through	the	mucosal	surface.7	The	52 
nasal	 route	 has	 been	 used	 to	 deliver	 vaccines	 for	 respiratory	 infections	 and	 sexually	53 
transmitted	infections.8	The	rationale	for	targeting	mucosal	tissue	in	the	genital	tracts	can	be	54 
attributed	to	the	mucosal	immune	system.		55 
	56 
The	Mucosal	Immune	System	57 
The	 mucosal	 immune	 system	 provides	 local	 protection	 against	 pathogens	 that	 enter	 the	58 
body	through	the	mucosal	membranes.	The	mucosal	 immune	activities	are	associated	with	59 
lymphoid	 tissues,	 i.e.	 mucosa-associated	 lymphoid	 tissue	 (MALT),	 which	 is	 present	 in	60 
mucosal	 tissue	 in	 the	 nose,	 lungs,	 gastrointestinal	 tract	 and	 vaginal/rectal	 surfaces.9	 The	61 
MALT	 is	classified	 into	specific	subcompartments,	depending	on	the	 location,	 including	the	62 
gut-associated	 lymphoid	 tissue	 (GALT),	 nasopharynx-associated	 lymphoid	 tissue	 (NALT),10	63 
bronchus-associated	 lymphoid	 tissue	 (BALT).	 The	 mucosal	 routes	 commonly	 used	 for	64 
vaccination	strategies	are	depicted	in	Figure	1.	The	mucosal	immune	systems	are	protected	65 
by	 immune	 cells	 that	 populate	 the	 region	 along	 the	mucosal	 surfaces,	 and	 also	 epithelial	66 
cells	 and	 mucus	 that	 acts	 as	 physical	 barrier	 before	 the	 pathogen	 gain	 access	 to	 the	67 
underlying	tissues.		68 
	69 
[Figure	1	near	here]	70 
	71 
Respiratory	Epithelial	Cells	72 
The	 epithelial	 cell	 layers	 cover	 the	 mucosal	 surfaces	 including	 the	 respiratory,	73 
gastrointestinal	and	urogenital	tracts	exposed	to	the	outer	environments.	The	epithelial	cell	74 
layer	acts	as	a	barrier	 that	 is	equipped	with	some	supporting	elements	such	as	 the	mucus	75 
and	cilia	in	preventing	penetration	of	pathogens	(Figure	2).		76 
Furthermore,	 the	 epithelial	 cells	 can	 detect	 and	 uptake	 pathogenic	 organisms	 and/or	77 
antigenic	 components	 by	 performing	 nonspecific	 endocytosis	 or	 interacting	 with	 pattern	78 
recognition	receptors	such	as	Toll-like	receptors	(TLRs).11-14	The	epithelial	cells	together	with	79 
lymphocytes	 and	 underlying	 antigen	 presenting	 cells	 (e.g.	 dendritic	 cells	 (DCs)	 and	80 
macrophages),	 cytokines	 and	 chemokines	 perform	 an	 innate,	 non-specific	 and	 adaptive	81 
immune	 response	 to	 encounter	 the	 invasion	 of	 pathogenic	 organisms	 or	 immunogenic	82 
substances.	14,15		83 
	84 
[Figure	2	near	here]	85 
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Nasopharynx-Associated	Lymphoid	Tissue	(NALT)	86 
The	NALT	can	be	simply	defined	as	organized	mucosal	immune	system	in	the	nasal	mucosa	87 
that	 consist	of	 lymphoid	 tissue,	B	cells,	T	 cells	and	antigen	presenting	cells	 (APCs)	and	are	88 
covered	 by	 an	 epithelial	 layer	 containing	 memory	 (M)	 cells.16	 M	 cells	 are	 present	 in	 the	89 
epithelial	 cell	 layers	 and	 have	 specialization	 in	 transporting	 antigen	 across	 the	90 
epithelium.17,18		91 
	92 
Whenever	the	nasal	mucosa	 is	exposed	to	pathogens	or	antigenic	substances,	the	 intruder	93 
will	 interact	with	the	mucosal	 immune	system.	The	type	of	 interaction	 is	highly	dependent	94 
on	the	characteristics	of	the	antigen.	The	pathogen	or	immunogenic	substances	may	be	able	95 
to	pass	through	the	nasal	epithelium	and	 interact	with	the	APCs	such	as	macrophages	and	96 
DCs.	 These	 APCs	 will	 process	 the	 antigen	 and	 migrate	 to	 the	 lymph	 node	 where	 the	97 
immunogenic	 portion	 will	 be	 presented	 to	 the	 T	 cells.	 This	 marks	 the	 activation	 of	 the	98 
immune	 response	 cascade.	 A	 soluble	 antigen	 might	 be	 recognized	 by	 the	 APCs,19	 while	99 
particulate	antigen	is	generally	taken	up	by	the	M	cells	and	transported	to	the	NALT.20	The	100 
NALT	 is	 also	 drained	 to	 the	 lymph	 node	 where	 further	 antigen	 processing	 will	 occur.	 A	101 
schematic	representation	of	 this	process	 in	more	detail	mechanisms	 is	presented	 in	Figure	102 
321.		103 
[Figure	3	near	here]	104 
	105 
Immunoglobulin	A	(IgA)	106 
In	 addition	 to	 the	 MALT,	 the	 mucosal	 immune	 system	 also	 produces	 the	 antibody	107 
immunoglobulin	 A	 (IgA),	 that	 plays	 an	 important	 role	 in	 mucosal	 immunity	 at	 mucosal	108 
surfaces.22	 IgA	constitutes	up	to	15	%	of	the	total	 immunoglobulin,	which	is	predominantly	109 
present	in	external	secretions	including	the	mucus	in	the	bronchial,	urogenital	and	digestive	110 
tracts,	saliva	and	tears.23	It	was	found	that	the	production	of	IgA	in	humans	could	be	over	1	111 
mg/ml	 in	 secretions	associated	with	 the	mucosal	 surfaces.18	A	small	amount	of	 IgA	can	be	112 
found	 in	 the	 serum	 while	 most	 of	 the	 IgA	 is	 located	 in	 external	 secretions	 known	 as	113 
secretory	IgA	(sIgA).24	IgA	consist	of	a	dimer	or	tetramer,	a	joining	J-chain	polypeptide	and	a	114 
polypeptide	chain	called	the	secretory	component.	24,	25	IgA	has	several	functions	in	mucosal	115 
defense	including	the	entrapment	of	antigens	or	pathogens	in	mucus	to	prevent	them	from	116 
direct	 contact	 with	 the	 mucosal	 surface.15,	26	 In	 addition,	 sIgA	 may	 also	 block	 or	 provide	117 
steric	 hindrance	 to	 surfaces	 of	 pathogenic	molecules	 that	may	 inhibit	 their	 attachment	 to	118 
the	epithelium.27	119 
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The	 predominance	 of	 IgA	 in	 mucosal	 areas	 is	 a	 result	 of	 mutual	 collaboration	 between	120 
plasma	cells	and	epithelial	cells.	The	activated	plasma	cells	in	the	lamina	propria,	adjacent	to	121 
mucosal	 surfaces	 produce	 polymeric	 IgA	 (pIgA),	 while	 the	 epithelial	 cells	 in	 the	 mucosal	122 
surfaces	 express	 an	 Ig	 receptor	 called	 the	 polymeric	 Ig	 receptor	 (pIgR).	 The	 released	 pIgA	123 
from	activated	plasma	cells	binds	to	pIgR,	and	is	then	taken	up	into	the	cell	via	endocytosis.	124 
IgA	 is	 transported	 across	 mucosal	 epithelial	 cells	 before	 being	 released	 onto	 the	 luminal	125 
surface	of	the	epithelial	cells.	Proteolysis	cleavage	of	the	pIgR	allows	IgA	to	be	secreted	into	126 
mucosal	secretions.	15,	25,	28		127 
	128 
Mucosal	Vaccines		129 
New	vaccine	formulations	should	be	able	to	induce	innate	and	adaptive	immune	response;	130 
involving	antigen-specific	memory	T	and	B	cells	that	will	respond	effectively	to	the	invading	131 
pathogens.29,	30	 Interaction	with	pathogens	or	antigens	can	produce	the	IgA	secretion	as	an	132 
antibody	 response.31	 Intracellular	 antigens,	 can	 be	 produced	 by	 invading	 viruses	 that	133 
replicate	within	 the	 host	 cell,	 or	 derive	 from	 cytoplasmic	 bacteria,	 while	 the	 extracellular	134 
antigens	 include	 bacteria,	 parasites,	 and	 toxins	 in	 the	 tissues.	 Intracellular	 antigens	 are	135 
generally	processed	in	the	host	cells,	coupled	to	a	major	histocompatibility	complex-I	(MHC-136 
I),	a	cell	surface	molecule,	and	transported	to	the	cell	surface.32,32	The	presence	of	MHC-I	on	137 
the	 cell	 surface	will	 lead	 to	 activation	 of	 CD8+	 T-cells	 to	 become	 cytotoxic	 T-lymphocytes	138 
(CTLs).	 Extracellular	 antigens	 are	 endocytosed	 and	 presented	 on	 MHC-II	 molecules	 for	139 
activation	of	CD4+	T-helper	(Th)	cells.32-34		140 
	141 
The	activation	of	Th	cells	will	release	a	specific	set	of	cytokines	that	modulate	the	B	cell	and	142 
CD8+	CTL	immune	response,	depending	on	the	nature	of	the	stimulant.35	Th	cell	types	Th-1,	143 
Th-2	 or	 Th-17	 will	 be	 induced	 accordingly.	 A	 Th-1	 response	 develops	 in	 the	 presence	 of	144 
interleukin	12	(IL-12),	which	is	in	turn	synthesized	primarily	by	DCs	and/or	natural	killer	(NK)	145 
cells	in	the	presence	of	bacteria	or	virus.	The	Th-1	response	is	marked	by	the	production	of	146 
the	Th-1	cytokines	e.g.	interferon-gamma	(IFN-γ)	and	tumour	necrosis	factor-beta	(TNF-b).	A	147 
Th-2	 response	 is	 driven	 by	 the	 presence	 of	 IL-4	 and	 results	 in	 the	 production	 of	 specific	148 
cytokines	 IL-4,	 IL-5,	 IL-9	and	 IL-13.36	 It	 can	be	seen	 that	 the	production	of	 IL-4	generates	a	149 
feedback	loop	that	results	in	increased	generation	of	a	Th-2	response	at	the	local	site.		150 
	151 
Nasal	 vaccination	 can	 also	 result	 in	 stimulation	 of	 Th-17	 CD4+	 cells.	 Th-17	 cells	 are	152 
responsible	for	the	secretion	of	the	proinflammatory	interleukins	IL-17A	and	IL-22,	as	well	as	153 
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IL-17F	 and	 IL-21.	 It	 Is	 known	 that	 the	 Th-17	 family	 of	 cytokines	 respond	 to	 extracellular	154 
bacterial	and	fungal	pathogens,	and	Th-17	cells	enhance	generation	of	Th-1	cells	through	an	155 
increased	 IFN-g	 activation	 giving	 rise	 to	 a	 Th-1/Th-17	 immune	 response	 that	 activates	156 
macrophages	 and	 other	 innate	 responses.36-38	 Stimulation	 of	 epithelial	 cells	 by	 the	 Th-17	157 
family	of	cytokines	can	aid	tissue	repair	and	secretion	of	antimicrobial	peptides,	which	can	158 
exert	a	protective	effect	in	pulmonary	infection.39	There	is	contradictory	evidence,	however,	159 
regarding	 the	 role	 of	 Th-17	 response	 in	 nasal	 immunization.	 Early	work	 on	 the	 role	 of	 Th	160 
polarization	 in	 nasal	 immunization	 indicated	 that	 this	 route	 always	 promotes	 a	 Th-17	161 
response. 40	 Later	 research	 has	 indicated	 that	 the	 response	 is	 more	 nuanced,	 with	 some	162 
contradictory	evidence	regarding	advantages	and	disadvantages	of	IL-17A	induction.41,42,	43 163 
Predominance	of	one	set	of	cytokines	over	the	other	is	generally	indicative	of	polarization	of	164 
Th	responses,	for	example	the	presence	of	IL-4	and	absence	of	IFN-γ	indicate	a	classical	Th-2	165 
polarized	 immune	 reaction44	 although	 these	 cytokines	 can	 also	 be	 released	 at	 the	 same	166 
time.45,46,	 47	 The	 varying	 cytokine	 profiles	 related	 to	 CTL	 and	 antibody	 production	 are	167 
fundamental	 in	 affording	 protection	 against	 a	 specific	 pathogen.	 Specific	 macrophage	168 
activation	was	found	to	play	a	crucial	role	in	the	eradication	of	Mycobacterium	tuberculosis	169 
bacterial	 infections,48	showing	that	 the	 induction	of	specific	 immune	responses	may	play	a	170 
key	role	in	determining	whether	a	given	vaccine	product	is	effective.	171 
	172 
The	 recently	discovered	 innate	 lymphoid	 cells	 (ILCs)	 act	 as	 an	early	 source	of	 cytokines	 to	173 
regulate	and	direct	mucosal	immune	responses. 49	Unlike	B	or	T	cells,	however,	they	do	not	174 
exhibit	 antigen	 specificity.	 Group	 1	 ILCs	 (ILC1s)	 include	 NK	 cells	 and	 produce	 Th-1	 type	175 
cytokines	IFN-γ	and	tumor	necrosis	factor-α	(TNF-α	);	group	2	ILCs	(ILC2s)	produce	Th-2	type	176 
cytokines	 IL4,	 IL-5	and/or	 IL-13,	while	group	3	 ILCs	 (ILC3s)	 include	 lymphoid	 tissue	 inducer	177 
cells	that	produce	Th-17	type	cytokines	IL-17	and/or	IL-22.	Both	ILC1s	and	ILC3s	have	been	178 
implicated	 in	 type	 1	 and	 Th17	 cell-mediated	 immunity	 and	 disease.50	 Because	 they	 are	179 
involved	in	early	release	of	cytokines	at	mucosal	sites,	ILCs	have	been	implicated	in	directing	180 
immune	response	at	the	mucosal	surface,	as	shown	by	a	number	of	recent	studies.	51,	52	NK	181 
cells	 and	 ILC1-like	 cells	 damped	 the	 immune	 response	 after	 vaginal	 administration	 of	182 
ovalbumin	 and	 cholera	 toxin	 to	 mice.53	 NK	 cells	 have	 been	 shown	 to	 enhance	 Th	183 
proliferation	through	IFN-γ	production,	54	while	ILC2s	play	a	role	in	directing	Th-2	response.55	184 
There	 is	 also	 evidence	 that	 ILCs	 can	 act	 as	 APCs,	 although	 this	 may	 be	 specific	 to	 the	185 
lymphoid	 tissue	 site	 involved	 and	 is	 thought	 to	 occur	 to	 a	 lesser	 extent	 than	 through	 the	186 
professional	 APCs.55	 Finally	 the	 regulatory	 T-cells	 (Tregs)	 play	 a	 role	 in	 ILC	 and	 Th	187 
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communication,54	 as	 well	 as	 helping	 to	 directly	 control	 Th	 response,	 which	 is	 particularly	188 
important	in	autoimmune	dysfunction	discussed	later.56		189 
	190 
Advantages	of	nasal	vaccine	delivery		191 
The	nasal	route	has	great	potential	for	vaccination	due	to	the	organized	immune	systems	of	192 
the	nasal	mucosa.	The	nasal	epithelium	encloses	follicle-associated	lymphoid	tissues	that	are	193 
important	 in	 inducing	mucosal	 immune	response.	The	 immune	cells	 such	as	nearby	B-cells	194 
can	 produce	 IgA	 at	 the	 mucosal	 sites	 where	 the	 respiratory	 pathogens	 invade.57	 Many	195 
published	 studies	 have	 shown	 that	 nasally	 administered	 vaccines	 induce	 serum	 IgG	 and	196 
mucosal	 IgA	 that	 are	 important	 for	 deliberating	 enhanced	 efficacy	 of	 vaccine.57,	 58	 The	197 
enhanced	 induction	of	mucosal	 IgA	antibodies	has	been	shown	to	play	a	significant	role	 in	198 
neutralizing	 pathogens	 such	 as	 Streptococcus	 pneumonia59	 	 and	 measles	 viruses60	 and	199 
preventing	further	 infection.	Moreover,	 intranasal	 immunization	has	also	been	reported	to	200 
induce	cross-reactive	antibodies	that	might	be	indicative	of	cross-protection.61,	62	This	effect	201 
can	make	 vaccines	more	 efficient	 by	 reducing	 the	 number	 of	 vaccinations	 required	 since	202 
cross-protective	 vaccines	may	produce	 cross-reactive	 antibodies	 that	 recognize	more	 than	203 
one	antigen.	Given	the	high	cost	of	many	antigen	production	systems	this	offers	a	distinct	204 
advantage	over	other	routes.			205 
	 	206 
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	207 
Therapeutic	vaccines	208 
While	 much	 of	 the	 work	 on	 nasal	 vaccine	 delivery	 is	 currently	 focused	 on	 prophylactic	209 
vaccines,	the	access	that	the	nasal	route	provides	to	the	mucosal	 immune	system	also	has	210 
relevance	 for	 therapeutic	 vaccines	 used	 to	 treat	 rather	 than	 prevent	 disease.	 Nasal	211 
immunotherapy	 for	 treatment	of	various	cancers	and	Alzheimer’s	are	currently	generating	212 
much	interest.	63,64	A	particular	focus	is	the	use	of	therapeutic	vaccines	for	the	treatment	of	213 
autoimmune	diseases	such	as	type	I	diabetes,	atherosclerosis,	multiple	sclerosis,	rheumatoid	214 
arthritis,	 lupus	 and	 Crohn's	 disease.	 These	 are	 caused	 by	 unchecked	 immune	 response	 to	215 
molecules,	termed	self-antigens,	that	are	capable	of	inducing	an	immune	response	in	a	host	216 
but	 should	 not	 induce	 an	 immune	 response	 in	 a	 healthy	 individual	 that	 produces	 them,	217 
whereas	 undesirable	 response	 to	 innocuous	 environmental	 antigens	 gives	 rise	 to	 allergy.	218 
The	autoimmune	and	inflammatory	response	is	governed	by	regulatory	T-cells	(Tregs),	with	219 
poor	 function	 or	 reduced	 numbers	 of	 Tregs	 being	 associated	 with	 autoimmune	 disease.	220 
Treatments	 for	 this	 family	of	diseases	are	often	non-specific,	or	use	 immune	suppressants	221 
that	increase	susceptibility	to	infection.	Development	of	effective	therapeutic	vaccine	would	222 
correct	 the	 inappropriate	 immune	 response	 through	 generation	 of	 tolerance	 to	 the	 self-223 
antigen(s).	65		Treg	cells	 that	express	 the	 forkhead	box	P3	 transcription	 factor	are	known	as	224 
FoxP3+T-cells,	with	dysfunction	of	this	subset	of	Tregs	being	implicated	in	a	range	of		chronic	225 
inflammatory	disorders.66	It	has	long	been	known	that	oral	delivery	is	effective	in	generating	226 
antigen	tolerance,	through	deliberate	introduction	of	the	antigen	to	food.67		More	recently	it	227 
has	been	shown	that	a	similar	tolerance	induction	can	be	achieved	via	nasal	delivery	through	228 
activation	of	the	DCs	in	the	draining	lymph	nodes		to	enhance	induction	of	FoxP3+T-cells. 68		229 
Examples	of	 successful	nasal	delivery	 include	 immunization	 to	 suppress	atherosclerosis69,70	230 
and	arthritis. 71	The	effect	of	adjuvant	on	tolerance	is	discussed	in	a	later	section.	231 
	232 
Formulation	approaches		233 
Current	 nasal	 formulations	 include,	 solutions	 (drops	 or	 sprays),	 powders,	 gels	 and	 solid	234 
inserts. 72	Solutions	are	often	described	in	the	literature	as	they	are	both	the	easiest	way	of	235 
formulating	a	vaccine	for	an	in	vivo	study	or	clinical	trial,	and	are	the	easiest	to	administer	236 
for	example	 in	mice	where	 the	 liquid	 is	often	pipetted	directly	 into	 the	nostril.	 In	humans	237 
this	often	means	that	the	subject	either	has	to	remain	laying	down	or	with	their	head	held	238 
back	 for	 a	period	of	 time	after	 administration,	which	 is	 not	 realistic	 in	 a	mass	 vaccination	239 
setting.	Sprays	are	easier	to	administer	and	deliver	vaccine	further	into	the	nasal	cavity,	but	240 
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may	still	 leak	out	of	 the	nostril	or	drip	 into	 the	oral	cavity.	 Including	a	gelling	agent	 in	 the	241 
formulation	 that	 is	 either	 mucoadhesive	 or	 able	 to	 penetrate	 through	 mucus	 offers	242 
increased	residence	time,	while	advantages	of	solid	formats	such	as	powders	or	solid	inserts	243 
include	 ease	 of	 manufacture	 and	 stability,	 while	 liquids	 are	 more	 prone	 to	 degradation.	244 
Taste	may	also	be	a	 factor	 as	 formulations	may	 travel	 into	 the	oral	 cavity,	 although	given	245 
that	 vaccines	 tend	 to	 be	 administered	once	or	 twice	only,	 this	 is	 less	 of	 an	 issue	 than	 for	246 
medicines	that	are	taken	on	a	regular	basis.			247 
	248 
A	 range	 of	 naturally-occurring,	 synthetic	 and	 semi-synthetic	 polymers	 have	 been	249 
investigated	 as	 gelling	 agents	 in	 nasal	 delivery	 of	 vaccine.	 Administering	 as	 a	 gel	 should	250 
improve	 retention,	 although	 there	 is	 ongoing	 debate	 as	 to	 whether	 positively	 charged	 or	251 
anionic	 polymers	 offer	 better	 uptake.	 Those	 that	 have	 the	 ability	 to	 adhere	 to	 mucosal	252 
surfaces	and	selectively	target	M	cells	or	APCs,	should	be	the	most	effective.	18,	26	Chitosan	253 
has	 been	 much	 investigated,	 and	 is	 a	 polysaccharide	 manufactured	 from	 chitin	 found	 in	254 
crustacean	shells	or	fungi	by	a	deacetylation	process.	 	Because	of	the	range	of	sources	this	255 
polymer	is	available	in	a	range	of	molecular	weights,	but	all	are	made	up	of	repeating	units	256 
of	 glucosamine	 and	 N-acetylglucosamine	 and	 bear	 a	 positive	 charge	 making	 it	257 
mucoadhesive.	Varying	the	degree	of	deacetylation	affects	the	charge,	as	does	methylation.		258 
Methylating	chitosan	offers	some	advantages	for	mucosal	delivery.		259 
	260 
Powder	formats	have	the	advantage	of	increased	stability	over	their	liquid	counterparts	and	261 
ability	to	target	further	 into	the	nasal	cavity.	An	example	of	this	 is	the	Anthrax	spray-dried	262 
powder	 formulation	 suitable	 for	 mass	 vaccination	 in	 developed	 and	 developing	 world	263 
settings.73	Possible	disadvantages	of	powders	include	the	ease	and	cost	of	administration	if	264 
specialist	 applicators	 are	 required.	 Solid	 inserts	 are	 tablets	 designed	 to	 dissolve	 when	 in	265 
contact	with	mucus	 and	 have	 been	 investigated	 for	 vaginal	 delivery	 in	 humans	 and	 nasal	266 
delivery	in	livestock	animals,	74,75	and	have	many	similarities	with	sublingual	formulations.	267 
	268 
Soluble	 antigens	 tend	 to	 be	 less	 immunogenic	 than	 particulate	 formulations,	 additionally	269 
encapsulating	 antigen	 into	particles	may	 improve	 the	 transport	of	 the	antigens	 across	 the	270 
nasal	 mucosa.	 For	 this	 reason	 there	 has	 been	 a	 great	 interest	 in	 developing	 particulate	271 
systems	 as	 carriers	 for	 vaccine	 products.76-78	 Aspects	 such	 as	 vaccine	 formulations	 and	272 
delivery	strategies	are	important	in	designing	new	vaccines	so	that	efﬁcient	induction	of	the	273 
innate	and	adaptive	immune	response	can	be	obtained	according	to	the	target	pathogen.18,	274 
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26	Particulate	delivery	 systems	 that	can	 imitate	pathogens	 such	as	polymeric	nanoparticles	275 
and	liposomes	are	considered	a	promising	approach	for	nasal	vaccine	delivery.	276 
Nanoparticles	 are	 particles	 in	 the	 nanometer	 1x10-9	 m	 size	 range	 and	 can	 be	 made	 of	277 
polymers	such	as	chitosan,	alginate	or	synthetic	co-polymers	such	as	poly(lactic-co-glycolic	278 
acid	 (PLGA).	Varying	 the	molecular	weight	and/or	 ratio	of	 lactic	 to	glycolic	acid	affects	 the	279 
rate	of	degradation	enabling	rate	of	release	to	be	controlled.	But	PLGA	nanoparticles	bear	a	280 
negative	 charge,	 which	 is	 not	 compatible	 with	 mucosal	 delivery,	 hence	 the	 plethora	 of	281 
papers	 investigating	 various	 coatings	 or	 modifications	 to	 adjust	 this.	 Those	 with	 positive	282 
charge	and	enhanced	residence	have	tended	to	give	the	best	immunological	responses	with	283 
high	 serum	antibody	 titers	 and	 sIgA	 levels.79	Poly(lactic	 acid)	 (PLA)	 and	polyethylene	glycol	284 
(PEG)	 can	 also	 be	 combined	 to	 form	 co-block	 polymers	 able	 to	 incorporate	 antigen	 80,		285 
varying	the	molecular	weight	of	the	PEG	and/or	ratio	of	PEG	to	PLA	alters	physicochemical	286 
characteristics,	release	and	hence	efficacy.81	287 
Other	 polymers	 investigated	 include	 pullulan,	 a	 naturally	 occurring	 polysaccharide	288 
copolymer	 made	 up	 of	 maltotriose	 subunits	 from	 fungus;82	 pectin,	 a	 naturally	 occurring	289 
polysaccharide	found	in	fruits;	and	the	biodegradable	synthetic	polymer	polycaprolactone.	83	290 
Liposomes	are	nano-	or	micrometre	 sized	particles	made	up	of	one	or	more	 lipid	bilayers,	291 
which	 have	 the	 ability	 to	 incorporate	 antigen	 at	 their	 surface	 or	 inside	 the	 aqueous	 core.	292 
There	 are	 numerous	 examples	 of	 coated	 and	 un-coated	 liposomal	 formulations	 used	 to	293 
deliver	vaccine	 intranasally	 in	a	range	of	 formats.84-90	Chen	showed	that	trimethylchitosan-294 
coated	 liposome	 powders	 offered	 improved	 uptake	 in	 ex	 vivo	 nasal	 penetration	 studies	295 
when	 compared	 with	 the	 same	 liposomes	 coated	 in	 chitosan.91	 Liposomes	 that	 also	296 
comprise	 lipid	or	other	material	derived	 from	virus	are	known	as	virosomes,	with	material	297 
from	influenza	virus	such	as	hemagglutinin	(HA)	and	neuraminidase	being	commonly	used.	298 
92-102		299 
Currently	 there	 is	 more	 evidence	 to	 support	 the	 hypothesis	 that	 particles	 smaller	 than	300 
300nm	are	 the	most	 effective	 at	 crossing	mucus,	 103	 but	 there	 is	 also	 evidence	 to	 suggest	301 
that	 larger	 particles	 are	 also	 able	 to	 penetrate.	 Results	 from	 intranasal	 administration	 of	302 
mucoadhesive	 microparticles	 suggest	 that	 penetration	 of	 the	 entire	 particle	 may	 not	 be	303 
necessary	to	 induce	an	immune	response.104	 It	 is	 likely	that	the	overall	combination	of	size	304 
and	 charge	 are	 key	 to	 achieving	 maximum	 immunological	 effect.	 Some	 examples	 of	305 
particulate	delivery	systems	investigated	for	nasal	delivery	of	vaccine	are	shown	in	Table	1.		306 
	307 
[Table	1	near	here]	308 
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	309 
Adjuvants	310 
Some	materials	 added	 to	 form	 gels	 or	 particles	 may	 act	 as	 adjuvants	 as	 well	 as	 delivery	311 
vehicles.	 Alternatively,	 adjuvants	 may	 be	 added	 as	 a	 separate	 component	 to	 a	 vaccine	312 
product.	Adjuvants	are	materials	added	to	a	vaccine	to	boost	the	immune	response	and	may	313 
also	 reduce	 the	 amount	 of	 antigen	 required	 to	 elicit	 an	 immune	 response.	 Alum	 is	 often	314 
used	 in	 traditional	 vaccines	 but	 is	 not	 effective	 when	 administered	 mucosally.	 Judicious	315 
choice	of	adjuvant	can	direct	the	arm	of	the	immune	system,	as	described	previously.	Often	316 
particulate	delivery	systems	are	believed	to	confer	both	 the	benefits	of	optimised	delivery	317 
across	 mucus/mucosal	 tissue	 and	 inherent	 adjuvanting	 effects.	 Many	 studies	 have	318 
investigated	 these	 abilities	 and	ascribed	 immune	boosting	 response	 to	one,	 other	or	both	319 
qualities.26	320 
Mucosal	 adjuvants	 that	 have	 been	 tested	 for	 intranasal	 vaccine	 delivery	 including:	 MF59	321 
emulsion	(containing	squalene	oil,	the	surfactants	Span	85	and	Tween	80	and	citrate	buffer)	322 
105,	 106,	 lipopolysaccharide,	 84,	 107	 TLR	 agonists,41,108,109	 chitosan,	 110	 trimethylchitosan,91	 110	323 
bacterial	 outer	 membrane	 protein111	 and	 cholera	 toxin112	 or	 heat-labile	 enterotoxin	 (LT)	324 
from	E.coli.113	Some	side	effects	have	been	found	with	the	use	of	bacterial	toxin	when	given	325 
intranasally,	 including	 Bell’s	 palsy	 (Facial	 paralysis)	 and	 other	 adverse	 events	 related	 to	326 
disorders	of	 the	 facial	nerves.114-116	 It	has	been	 suggested	 that	 the	 central	nervous	 system	327 
was	 involved	 in	 the	palsy	as	 the	bacterial	 toxin	was	re-directed	 into	 the	brain.	 115,	117	Thus,	328 
the	use	of	 LT	as	 vaccine	adjuvant	 is	no	 longer	 recommended.	Mast	 cell	 activators	 such	as	329 
compound	 48/80	 (C48/80)	 have	 shown	 promise	 in	 Anthrax	 vaccine.73	 As	 described	330 
previously,	adjuvants	can	help	to	polarize	immune	response	and	this	effect	should	be	taken	331 
into	account	when	considering	adjuvant	for	a	particular	vaccine	type.	Mice	immunized	with	332 
an	influenza	vaccine	adjuvanted	with	a	synthetic	TLR-4	agonist	via	the	nasal	route,	exhibited	333 
a	transient,	enhanced	 IL-17A	pathology,	characterised	by	weight	 loss	and	morbidity,	which	334 
was	significantly	greater	than	observed	in	mice	given	no-adjuvanted	antigen.41	The	effect	of	335 
adjuvants	on	induction	of	tolerance	has	also	been	noted;	an	intranasal	co-administration	of	336 
hen	 egg	 lysozyme	with	 a	 TLR2	 ligand	 enhanced	 Th1-type	 antibodies	 in	 one	 case, 118	while	337 
another	TLG2	 ligand,	Pam3Cys,	was	 shown	to	 increase	 the	 risk	of	developing	autoimmune	338 
disease	 119	 PLGA	 nanoparticles	 have	 been	 shown	 to	 boost	 tolerance	 in	 suppression	 of	339 
arthritis	120	and	further	research	by	the	same	group	has	shown	that	they	are	responsible	for	340 
generation	of	enhanced	Treg	cell	induction.68			341 
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	343 
Current	nasal	vaccine	products	344 
Licensed	 intranasal	 vaccines	 for	 humans	 include	 the	 influenza	 vaccines	 FluMist/Fluenz™	345 
(MedImmune,	 MD,	 USA)121	 	 and	 the	 Nasovac™	 live	 attenuated	 influenza	 nasal	 spray	346 
manufactured	 by	 the	 Serum	 Institute	 of	 India,	 which	 was	 developed	 alongside	 its	 live	347 
attenuated	 A(H1N1),	more	 commonly	 known	 as	 swine	 flu.122	 No	 serious	 side	 effects	 have	348 
been	 reported	 associated	 with	 the	 administration	 of	 Nasovac	 indicating	 its	 safety,123	349 
although	 its	 efficacy	 data	 are	 not	 sufficiently	 available	 yet.124	 Until	 recently	 FluMist	 was	350 
considered	 one	 of	 the	 most	 successful	 intranasal	 vaccines,	 it	 is	 well	 tolerated	 and	 had	351 
exhibited	 good	 efficacy.125	 A	 runny	 nose/nasal	 congestion	 has	 been	 reported	 as	 the	most	352 
common	adverse	events	of	Flumist,	with	mild	 to	moderate	 in	 severity.121	However	The	US	353 
CDC	 (Centre	 for	 Disease	 Control)	 Advisory	 Committee	 on	 Immunization	 Practices	 (ACIP)	354 
recently	 voted	 that	 	 the	 Flumist	 nasal	 spray	 live	 attenuated	 influenza	 vaccine	 (LAIV)	 (sic),	355 
should	 not	 be	 used	 during	 the	 2016-2017	 flu	 season,	 based	 on	 “data	 showing	 poor	 or	356 
relatively	lower	effectiveness	of	LAIV	from	2013	through	2016”.126	At	the	time	of	writing	no	357 
further	detail	was	available.	It	should	be	noted	that	a	nasal	Live	Attenuated	Influenza	Virus	358 
(LAIV)	influenza	vaccine	has	been	used	for	over	50	years	in	Russia	and	previously	the	USSR.	359 
Data	 published	 from	 a	 study	 using	 the	 Russian	 intranasal	 vaccine	 showed	 better	 herd	360 
immunity	for	 intranasal	LAIV	than	 inactivated	vaccine.127	Herd	 immunity	 is	a	crucial	 impact	361 
of	mas	vaccination	programs;	it	 is	the	immunity	given	to	the	whole	population,	even	those	362 
who	 have	 not	 received	 a	 vaccine,	 because	 enough	 of	 the	 population	 (the	 herd)	 have	363 
received	 the	 vaccine	 that	 the	 infection	 cannot	 effectively	 spread.	 However,	 it	 should	 be	364 
noted	that	the	Russian	LAIV	is	administered	in	2	doses	3	weeks	apart,	which	increases	cost	365 
and	has	the	possibility	of	reducing	compliance.		366 
Targeting	school	age	children	for	influenza	has	two	benefits,	first	this	age	group	tend	to	have	367 
the	highest	rates	of	 influenza	 infection.	Secondly	targeting	children	reduces	 infection	rates	368 
in	 through	 transmission	 from	 this	 group,	 although	 transmission	 rates	 can	 vary.128	 In	 the	369 
European	Union	an	intranasal	influenza	vaccine	was	licensed	in	2011.	Damm	et	al	explored	370 
the	possible	effect	of	 introducing	 this	product	 in	Germany	and	concluded	 that	 introducing	371 
the	 vaccine	 to	German	 schoolchildren	would	 lead	 to	 a	 “substantial	 reduction	 in	 influenza-372 
associated	 disease	 at	 a	 reasonable	 cost	 to	 the	 German	 statutory	 health	 insurance	373 
system”.129	 Researchers	 looking	 into	 the	 same	 question	 for	 Thailand	 reached	 similar	374 
conclusions	with	provisos	based	on	willingness	to	pay	and	contact	between	age	groups.	130	375 
This	 study	 raised	 the	 issue	of	effectiveness	across	countries	where	healthcare	systems	are	376 
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either	 new	 or	 emerging	 and	 differences	 in	 rates	 and	 timing	 of	 seasonal	 outbreaks.	 These	377 
findings	 highlight	 the	 differences	 between	 high	 and	 low-	 to	middle-income	 countries	 and	378 
demonstrate	 the	 need	 to	 carefully	 evaluate	 the	 target	 population	 and	 seasonal	 factors	379 
before	designing	or	selecting	a	vaccine	product.		380 
	381 
[Table	2	near	here]	382 
	383 
A	 recent	 review	 describes	 most	 of	 the	 commonly	 encountered	 nasal	 delivery	 devices	384 
currently	 on	 the	 market.	 72	 Additionally,	 there	 is	 a	 range	 of	 nasal	 delivery	 strategies	 at	385 
various	 stages	 along	 the	 pre-clinical-clinical	 pipe-line,	 some	 of	 these	 may	 be	 suitable	 for	386 
vaccine	delivery	either	in	their	current	formats	or	with	some	adaptation.	A	selection	of	these	387 
is	 shown	 in	 Table	 2	 and	 will	 be	 described	 briefly.	 Criticalsorb	 is	 a	 penetration	 enhancing	388 
formulation	 based	 on	 PLGA	 and	 PLA,	 developed	 by	 a	 spin-out	 from	 University	 of	389 
Nottingham,	UK,	currently	there	are	no	details	for	vaccine	application.	The	web-site	of	μco™	390 
System	 (Muco	 System)	 shows	 data	 for	 a	 nasal	 flu	 vaccine	 in	 a	 non-human	 primate	391 
immunogenicity	 study,	 stating	 that	 more	 sIgA	 was	 produced	 in	 the	 mucosal	 membrane	392 
compared	 to	 injection	 and	nasal	 liquid	 spray.	 and	4-times	 greater	 sIgA	 than	 a	 nasal	 liquid	393 
spray.131	Optinose	is	a	breath-actuated	device	for	delivering	powder	or	liquid,	a	schematic	of	394 
the	 device	 has	 been	 published	 in	 the	 literature,132	 as	 has	 data	 on	 the	 use	 of	 sumitriptan	395 
delivered	via	 the	Optinose	device133,	134.	Kurve	 is	a	device	 for	delivering	 liquid	 formulations	396 
“via	a	controlled,	turbulent	flow”, 135	the	makers	have	published	results	of	a	pilot	clinical	trial	397 
detailing	their	intranasal	insulin	therapy	for	Alzheimer’s	disease	and	amnestic	mild	cognitive	398 
impairment	 A,136	 while	 Archimedes	 Pharma	 developed	 a	 chitosan-based	 formulation,	399 
ChiSysâ	,	that	achieved	good	success	in	a	clinical	trial	for	a	Norovirus	vaccine.137	Because	of	400 
the	proprietary	and	often	pre-approval	nature	of	the	devices	described	(with	the	exception	401 
of	 Flumist/Fluenz	 and	 MAD	 Nasal),	 there	 is	 a	 paucity	 of	 information	 regarding	 design	 of	402 
some	 of	 the	 devices	 described	 in	 this	 section.	 The	 interested	 reader	 is	 referred	 to	 the	403 
relevant	 company	 web-sites	 (Table	 2),	 which	 will	 offer	 more	 current	 information	 than	 is	404 
possible	in	this	review.		405 
	406 
Conclusion	407 
Safety	profiles	are	yet	to	be	established	in	humans	for	many	of	the	formulation	approaches	408 
described	 in	 this	 review.	However,	 the	ever-increasing	 range	of	 clinical	 trials	 indicates	 the	409 
accepted	need	 for	 nasal	 vaccines	 that	 are	 easy	 to	 administer	 and	offer	 improved	benefits	410 
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over	other	mucosal	routes	in	terms	of	cost	of	formulation	and	need	for	skilled	personnel	to	411 
administer.	The	obvious	benefits	of	directly	stimulating	 the	mucosal	 immune	response	are	412 
clear,	but	as	yet	have	not	been	fully	realized	with	the	exception	of	those	for	influenza,	which	413 
demonstrate	 the	 efficiency	 of	 this	 route.	 The	 recent	 US	 CDC	 press	 release	 will	 no	 doubt	414 
impact	on	the	pharmaceutical	industry	view	of	riskiness	of	nasal	formats.	But	with	increased	415 
need	 to	 immunize	 large	 populations,	 potentially	 in	 swift	 response	 to	 pandemics	 such	 as	416 
avian,	 swine	 flu	 and	 Ebola	 there	 is	 a	 clear	 need	 to	 have	 strategies	 in	 place.	 The	 interplay	417 
between	 formulation	 or	 carrier	 and	 adjuvant	 in	 directing	 immune	 response	 should	 be	418 
investigated.	 Unfortunately,	 the	 high	 cost	 of	 clinical	 trials	 and	 issues	 with	 correlating	419 
immune	 responses	 in	 animal	 models	 with	 humans	 have	 created	 a	 bottleneck.	 There	 is	 a	420 
growing	body	of	evidence	to	suggest	that	genetic	material	can	be	successfully	delivered	via	421 
this	 route,	 while	 recent	 studies	 have	 also	 demonstrated	 the	 advantages	 associated	 with	422 
combining	 the	 nasal	 with	 other	 routes	 of	 delivery	 or	 even	 combining	 vaccine	 with	423 
microbicide.138	 	 This	 review	 has	 focused	 primarily	 on	 prophylactic	 vaccines	 but	 there	 is	424 
encouraging	evidence	that	nasal	delivery	will	have	a	role	to	play	in	the	design	of	therapeutic	425 
vaccines	for	e.g.	cancers	Alzheimer’s	and	autoimmune	diseases.	The	role	of	presentation	is	426 
also	 important	when	designing	pre-clinical	 studies	–	 instillation	of	drops	 is	 relatively	 facile	427 
even	 in	mice,	while	more	 advanced	 formulations	 require	more	 careful	 consideration	 than	428 
those	 administered	 via	 pipette.	 The	 design	 of	 ex	 vivo,	 cell	 culture	 or	 tissue	 models	 that	429 
provide	better	prediction	of	response	in	humans	is	extremely	desirable.	A	“one	size	fits	all”	430 
approach	is	not	appropriate	for	vaccine	design	where	factors	relating	to	target	population,	431 
disease	 type	 and	 mode	 of	 infection,	 will	 all	 impact	 on	 both	 formulation	 and	 antigen	432 
optimization.		433 
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Table	1	Examples	of	particulate	formulations	with	published	in	vivo	data.	435 
	436 
Particle	type	 Vaccine	 Study	type	 Key	findings	 Literature	
source	
Chitosan	and	HSA	
(human	serum	
albumin)	
Hepatitis	B	
Plasmid	DNA	
Female	C57/BL	
mice	compared	
with	plasmid	
DNA	alone	and	
protein	antigen	
humoral	and	
mucosal	immune	
response	
Lebre	et	al	
2016139	
	
polycaprolactone	
/chitosan	
	
Hepatitis	B	
surface	antigen	
(HBsAg)	
C57BL/6	mice	
IN	only.	Varying	
doses	of	HBsAg	
no	comparator	
formulations	
	
Dose-independent	
serum	IgG	and	nasal	
IgA	
Jesus	et	al	
201683	
TMC	 ovalbumin	
compared	with	
PLGA	and	TMC-
coated	PLGA		
Female	Balb/c	
compared	with	
PLGA	and	TMC-
coated	PLGA	
(IM	and	IN)	
Serum	IgG	superior	
to	other	IN	but	
inferior	to	all	IM	
Slutter	et	al	
2010	79	
	
chitosan	and	
glycol	chitosan	
	coated	PLGA	
HBsAg	
	
Female	BALB/c	
mice	compared	
with	chitosan	
coated	PLGA	
and	PLGA,	
HBsAg-Alum	
sub-cut.		
GC-PLGA	NPs	could	
induce	significantly	
higher	systemic	and	
mucosal	immune	
response	than	other	
IN	nanoparticles.	
Pawar	et	al	
2013140	
PEG-PLA	 HBsAg	
	
BALB/c	mice	
compared	with	
PLA	
nanoparticles	
and	
conventional	
alum-HBsAg	
based	vaccine	
Higher	systemic	and	
mucosal	response	
than	PLA			
Jain	et	al	
200980	
Liposomes	 Influenza	
plasmid	DNA	
(H1N1)	
hemagglutinin	
(HA)	
BALB/c	mice	
challenge	study	
IN	compared	
with	IM	DNA	
alone	(IN	and	
IM)	
Protective	effect	
against	challenge		 	
Wang	
et	al	
200485	
	
Esterified	
hyaluronic	acid	
microparticles	
Commercial	
Influenza	H1N1	
HA	and	LTK63	
or	LTR72	
adjuvants	
	
mice,	rabbits	
and	micro-pigs	
IN	compared	
with	soluble	HA	
+	LTK63,	or	IM	
with	HA	
	
	
Significantly	
enhanced	serum	IgG	
responses	and	
higher	
hemagglutination	
inhibition	(HI)	titers	
than	other	groups	
	
Singh	et	al	
2001104	
Glycol	chitosan	
coated	liposomes	
Hepatitis	B	
Plasmid	DNA	
BALB/c	mice	
prime	boost	
Humoral	mucosal	
and	cellular	
Khatri	et	al	
2008	141	
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compared	with	
DNA	alone	(IN)	
and	HBsAg	
protein	(IM)	
response	higher	
than	DNA	alone.	
Cellular	response	
better	than	IM	
protein	antigen	
	
Liposomes/	
hyaluronic	acid	
Yersinia	pestis	
(plague)	
C57BL/6	mice	
No	IM	
comparison	
Th1/Th2	humoral	
immune	response	
Fan	et	al	
2015	90	
	
Chitosan-coated	
PLGA		
foot-and-
mouth	disease	
plasmid	DNA		
Challenge	study	
in	cattle	
Higher	mucosal,	
systemic,	and	cell-
mediated	immunity	
than	Chitosan	-	
Inactivated	antigen	
nanoparticles	
Pan	et	al	
2014142	
Cationic	
cholesteryl-
group-bearing	
pullulan	
Clostridium	
botulinum	
type-A	
neurotoxin	
subunit	antigen	
BALB/c	mice	 Strong	tetanus-
toxoid-specific	
systemic	and	
mucosal	immune	
responses	
Nochi	et	al	
2010	82	
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	438 
Table	2	Currently	Marketed	Technology	for	Nasal	Delivery		439 
Name	 Company	 Presentation	 Drug	type	 Regulator
y	status	
Markete
d	
products	
Company	
web-site	
Criticalsorb	 Critical	
Pharmaceuti
cals	
Powder	or	
aerosol		
Small	
molecule	–	
peptide,		
HGH,insuli
n	
GRAS	
status?	
None	 www.crit
icalphar
maceutic
als.com	
µco™	 Nasal	
Delivery	
System	
Business	
Powder-
based	
mucoadhesi
ve	drug	
carrier	plus	
device	
Anti-
emetic		
Migraine,	
flu	vaccine	
Phase	II,		
	
Phase	I,	
pre-
clinical	
None	 www.snb
l-
nds.co.jp
/en/	
Optinose	 Optinose	 Powder	or	
liquid	plus	
device	
Small	
molecule	
Clinical	
trials	
(various)	
None	 optinose.
com/	
Kurve	 Kurve	 Liquid	plus	
device	
Includes	
Alzheimer’
s		
vaccine	
Phase	II		 None	 www.kur
vetech.c
om	
MAD	nasal	 Teleflex	 Liquid	plus	
device	
Attachme
nt	for	
syringe	to	
atomize	
liquids	
Device	
only/	not	
vaccines	
Markete
d	as	
stand-
alone	
device	
www.tel
eflex.co
m	
None	 Drug	
Delivery	
International	
Solid	insert	 Small	
molecules	
&		insulin	
None	
found	
None	
found	
www.bd
dpharma	
Flumist	
Fluenz	
MedImmune		
(AstraZeneca
)	
Nasal	gel	 Flu	vaccine	 FDA	&	
EMA	
Flumist	
Fluenz	
www.flu
mistquad
rivalent.c
om/	
Bacterial	S	
antigen	
pores	
Tufts	
University	-	
US	
Oral/nasal	
format	not	
stated	
Tetanus	
toxin		
and		
rotavirus	
VP6	
antigen	
None	 None	 www.tuft
s.edu/	
Vaccinetab	 Queen’s	
University	
Belfast,	UK	
Liposomal	
liquid,	
powder	or	
nasal	insert	
Small	
molecules	
and	
antigen	
GRAS	 None	 www.vac
cinetab.c
om	
ChiSys	 Archimedes	
Pharma	
Nasal	gel		 Small	
molecules	
and	
antigen	
Phase	I,	
pre-
clinical	
Small	
molecul
e	
	
	 18	
	440 
	 	441 
	 19	
	442 
Figure	Captions	443 
Figure	 1.	 Routes	 of	 mucosal	 vaccination	 within	 the	 mucosa-associated	 lymphoid	 tissue	444 
(MALT),	 with	 several	 subcompartments	 including:	 the	 nasopharynx-associated	 lymphoid	445 
tissue	 (NALT),	 bronchus-associated	 lymphoid	 tissue	 (BALT),	 gut-associated	 lymphoid	 tissue	446 
(GALT)	and	genital	tract-associated	lymphoid	tissue,	reproduced	from	Lycke	et	al,	2012.125	447 
Figure	 2.	 Structure	 and	 function	 of	 respiratory	 epithelial	 cells;	 equipped	with	mucus	 layer	448 
(not	shown)	and	ciliated	cells,	reproduced	from	Grassin-Delyle	(2012)143.	449 
Figure	3.	Pathways	demonstrating	how	particulate	antigen	triggers	local	immune	response	in	450 
the	 nasal	 mucosa	 and	 systemic	 immune	 response	 via	 the	 NALT,	 adapted	 from	 Csaba	451 
(2009)21.	452 
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